摘要
为了解单用氯沙坦、吲哒帕胺及两者联用对轻、中度高血压的降压效果与临床意义 ,将 6 1例轻中度高血压患者随机分为 3组 ,分别服用氯沙坦、吲哒帕胺及两联合用药 ,观察用药前及第 2、4周后的偶测血压、血糖、血脂、血尿酸、血钾等变化 ,并于用药前后行 2 4小时动态血压监测。结果表明 :用药 4周后单药与联用均有明显的降压效果 ,偶测与 2 4小时动态血压均显著降低 (P<0 .0 1) ,但联用的降压效果更明显 ,与单药比较有明显差异 (P<0 .0 5 )。用药第 2周时单用氯沙坦组较单用吲哒帕胺与联用组降压效果差 (P<0 .0 5 ) ,显示单用氯沙坦钾降压起效缓慢。实验室检查 :单用吲哒帕胺组血钾降低、血尿酸升高 (P<0 .0 5 ) ,单用氯沙坦组血尿酸降低 (P<0 .0 5 ) ,联用组无明显变化。因此认为 ,氯沙坦、吲哒帕胺联合应用具有良好的互补性作用 。
To evaluate the clincal efficacy of combined Losartan potassium with Indapamide as well as single Losartan K for mild to moderate essential hypertension, 61 patients with hypertention were separated into 3 groups randomly. Subjects were treated with Losartan potassium and Indapamide combined or single Losartan K. Occasional and dynamic blood pressure, blood sugar, blood lipid, blood uric acid and serum potassium were observed before and after administration. The results were that there was obvious efficacy for lowing blood pressure in all 3 groups after 4 weeks and both accasional and dynamic blood pressure decreased significantly( P <0.01). Compared with single drug, combined treatment for depressing was more obvious( P <0.05). Results also showed that there was a marked response on depression blood pressure as well as a lowing blodd uric acid over Losantan potassium group( P <0.05). Hypokalemia and hyperuricaemia can be seen in Indapamide group( P <0.05). But there were no significant changes for these blood examinations in combined treatment group. Conclusion was that it is effective and safe to combine with Losantan potassium and Indapamide in treatment of hypertension for their good complementary action.
出处
《药学进展》
CAS
2001年第5期303-307,共5页
Progress in Pharmaceutical Sciences
